P01.111 Using the ASCO and ESMO frameworks to assess the clinical value of tumor treating fields for newly diagnosed Glioblastoma multiforme

Por Proescholdt, C, Kelly, J, Kinzel, A, Bähr, O
Publicado no Neuro Oncol (2018)

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015

Por Rolfo, Christian, Caglevic, Christian, Bretel, Denisse, Hong, David, Raez, Luis E, Cardona, Andres F, Oton, Ana B, Gomez, Henry, Dafni, Urania, Vallejos, Carlos, Zielinski, Christoph
Publicado no ESMO Open (2016)

Nursing highlights from the 2015 European Cancer Congress (ECCO18–ESMO40), 25–29 September 2015, Vienna: reinforcing multidisciplinarity

Por Caruso, Rosario, Lichosik, Danuta
Publicado no Ecancermedicalscience (2015)

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

Por Hantson, Inge, Dooms, Christophe, Verbeken, Eric, Vandenberghe, Peter, Vliegen, Liesbet, Roskams, Tania, Borght, Sara Vander, Nackaerts, Kris, Wauters, Isabelle, Vansteenkiste, Johan
Publicado em 2014

Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7–10 October 2016

Por Davies, Will
Publicado no Ecancermedicalscience (2016)

Rituximab biosimilars open new horizons in immunotherapy

Por Jaeger, Ulrich
Publicado no ESMO Open (2017)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma

Por Dummer, Reinhard, Michielin, Olivier, Nägeli, Mirjam Chantal, M. Goldinger, Simone, Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara, Schadendorf, Dirk
Publicado no ESMO Open (2018)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

Por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado no ESMO Open (2017)

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a...

Por Grob, Jean-Jacques, Mortier, Laurent, D’Hondt, Lionel, Grange, Florent, Baurain, Jean Francois, Dréno, Brigitte, Lebbe, Céleste, Robert, Caroline, Dompmartin, Anne, Neyns, Bart, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F
Publicado no ESMO Open (2017)

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients...

Por Morgillo, Floriana, Fasano, Morena, Della Corte, Carminia Maria, Sasso, Ferdinando Carlo, Papaccio, Federica, Viscardi, Giuseppe, Esposito, Giovanna, Di Liello, Raimondo, Normanno, Nicola, Capuano, Annalisa, Berrino, Liberato, Vicidomini, Giovanni, Fiorelli, Alfonso, Santini, Mario, Ciardiello, Fortunato
Publicado no ESMO Open (2017)

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non...

Por Baba, Hideo, Yamada, Yasuhide, Takahari, Daisuke, Matsumoto, Hiroshi, Yoshida, Kazuhiro, Nakamura, Masato, Yoshida, Motoki, Iwamoto, Shigeyoshi, Shimada, Ken, Komatsu, Yoshito, Sasaki, Yasutsuna, Satoh, Taroh, Takahashi, Keiichi, Mishima, Hideyuki, Muro, Kei, Watanabe, Masahiko, Sakata, Yuh, Morita, Satoshi, Shimada, Yasuhiro, Sugihara, Kenichi
Publicado no ESMO Open (2017)

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study...

Por Yoshino, Takayuki, Oki, Eiji, Nozawa, Hiroaki, Eguchi-Nakajima, Takako, Taniguchi, Hiroya, Morita, Satoshi, Takenaka, Naruhito, Ozawa, Daisuke, Shirao, Kuniaki
Publicado no ESMO Open (2018)

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical U...

Por Kiesewetter, Barbara, Raderer, Markus, Prager, Gerald W, Fuereder, Thorsten, Marosi, Christine, Preusser, Matthias, Krainer, Michael, Locker, Gottfried J, Brodowicz, Thomas, Zielinski, Christoph C
Publicado no ESMO Open (2017)

In the literature: April 2017

Por Cervantes, Andrés
Publicado no ESMO Open (2017)

Cancer drugs, survival and ethics: a critical look from the inside

Por Piccart, Martine, Pondé, Noam
Publicado no ESMO Open (2017)

In the literature: February 2017

Por Cervantes, Andrés, Terol, María José
Publicado no ESMO Open (2017)

A new era of oncology through artificial intelligence

Por Curioni-Fontecedro, Alessandra
Publicado no ESMO Open (2017)

Biologics and biosimilars: what, why and how?

Por Chan, Juliana CN, Chan, Anthony TC
Publicado no ESMO Open (2017)

Male breast cancer: finding the way in this uncommon path

Por Maurer, Christian, Martel, Samuel, de Azambuja, Evandro
Publicado no ESMO Open (2017)

Essentials for clinicians: head and neck tumours and neuro-oncology

Por Le Rhun, Emilie
Publicado no ESMO Open (2017)